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Javed Mohammed1, Andrew Ryscavage2, Rolando Perez-Lorenzo1, Andrew J. Gunderson1,
Nicholas Blazanin1 and Adam B. Glick1
Overexpression of transforming growth factor-b1 (TGFb1) in the normal epidermis can provoke an
inflammatory response, but whether this occurs within a developing tumor is not clear. To test this, we
used an inducible transgenic mouse to overexpress TGFb1 in premalignant squamous lesions. Within 48 hours
of TGFb1 induction, there was an increase in IL-17 production by both CD4þ and gdþ T cells, together with
increased expression of T-helper-17 (Th17)-polarizing cytokines. Induction of TGFb1 in premalignant primary
keratinocytes elevated the expression of proinflammatory and Th17-polarizing cytokines, and the
keratinocyte-conditioned media caused IL-17 production by naive T cells that was dependent on T-cell
TGFb1 signaling. Microarray analysis showed significant upregulation of proinflammatory genes 2 days after
TGFb1 induction, and this was followed by increased MPOþ , F4/80þ , and CD8þ cells in tumors, increased
CD8þ effectors and IFNgþ cells in skin-draining LNs, and tumor regression. In parallel, the percentage of
tumor CD11bþLy6Gþ neutrophils was reduced. Neutralization of IL-17 blocked TGFb1-induced CD11bþ
Ly6G tumor infiltration but did not alter the reduction of neutrophils or tumor regression. Thus, TGFb1
overexpression causes IL-17-dependent and IL-17-independent changes in the premalignant tumor
inflammatory microenvironment.
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INTRODUCTION
Transforming growth factor-b1 (TGFb1) has both tumor-
suppressor and oncogenic activities that are cancer-
stage-specific (Glick, 2004). Although the cytostatic program
induced by TGFb1 suppresses the initial development of
tumors (de Caestecker et al., 2000), studies of humans and
human cancer lines show that TGFb1 is frequently
overexpressed in late-stage cancers, and this overexpression
accelerates tumor progression (Gorsch et al., 1992; Yang
et al., 2002; Tang et al., 2003; Tian et al., 2003), mediated in
part through TGFb1-mediated suppression of immunosurveil-
lance mechanisms (Gorelik and Flavell, 2001; Li et al.,
2006). TGFb1, along with IL-6 and other proinflammatory
cytokines such as TNF-a and IL-1b, also induces the
differentiation of the proinflammatory T-helper-17 (Th17)
T-cell lineage, which is implicated in the pathogenesis of a
number of autoimmune and chronic inflammatory diseases
(Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al.,
2006; Krueger et al., 2007). The role of IL-17 in
cancer pathogenesis is controversial (Kryczek et al., 2009b;
Muranski and Restifo, 2009; Wang et al., 2009), but in the
mouse two-stage skin carcinogenesis model, neutralization of
IL-17 delays 12-O-tetradecanoylphorbol-13-acetate (TPA)-
induced tumor promotion (Xiao et al., 2009). Long-term
overexpression of TGFb1 in the normal epidermis or oral
mucosa causes an inflammatory response that blocks the
TGFb cytostatic program and leads to severe hyperplasia (Liu
et al., 2001; Li et al., 2004; Lu et al., 2004). Although IL-17
is elevated in lesional and non-lesional skin of TGFb1
transgenic mice, maintenance of the inflammatory response
is independent of the IL-17 pathway (Fitch et al., 2009).
However, it is not known whether TGFb1 overexpression
within the context of a premalignant lesion would provoke a
similar inflammatory response. To study the effects of TGFb1
on the tumor immune microenvironment, we have generated
benign papillomas in the epidermis of mice expressing an
inducible TGFb1 transgene and examined acute effects after
induction of TGFb1. We find that TGFb1 provokes an
inflammatory response through IL-17 production by tumor-
infiltrating CD4þ and gdþ T cells, but this does not block
tumor regression.
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RESULTS
TGFb1 causes rapid regression in premalignant skin tumors
To determine the effects of TGFb1 overexpression on immune
response within the context of a premalignant squamous
lesion, we generated papillomas in single transgenic (ST) K5/
rTA and double transgenic (DT) K5/rTA tetOTGFb1 mice
with a two-stage skin carcinogenesis protocol before trans-
gene induction. The incidence and latency of papilloma
formation were similar between ST and DT mice (data not
shown). Forty-eight hours after treatment of tumor-bearing
mice with doxycycline (dox), expression of the tetOTGFb1
transgene was found only in DT papillomas (Figure 1a). There
was a significant increase in the number of DT tumor cells
with nuclear phospho-Smad2 staining (Figure 1b and c), and
rapid decrease in the percentage of proliferating tumor cells
(Figure 1d), indicating that the TGFb1 cytostatic program was
still intact in these premalignant tumors. Over 10 days on dox
treatment, there was a 5-fold decrease in the size of the DT
papillomas (Figure 1f), which was associated with increase in
TdT-mediated dNTP nick-end labeling (TUNEL)-positive cells
from a baseline of 15%, which were mainly in the terminally
differentiating cornified cells, to 37% (P¼ 0.028) in TGFb1-
expressing tumors (Figure 1e).
TGFb1 induces IL-17 expression in tumor-infiltrating CD4þ and
cdþ T cells
We next analyzed tumor-infiltrating lymphocytes from
individual papillomas by flow cytometry to test whether
TGFb1 could polarize T-cell differentiation toward a Th17
phenotype. In papillomas overexpressing TGFb1, there was a
significant increase in the percentage of CD4þ T cells
producing IL-17 as compared with that in control papillomas,
even though there was no overall change in the percentage of
CD4þ cells within the total population of infiltrating CD45þ
lymphocytes, and no change in the percentage of
IFNgþ CD4þ T cells (Figure 2a and b). A large fraction of
IL-17þ cells were CD4 gdTCRþ and these increased
approximately 2.5-fold after induction of TGFb1. In tumors
expressing TGFb1, we detected an increase in transcript
levels for IL-17, as well as for the Th17-polarizing cytokines
IL-6 and IL-23 (Figure 2c). mRNA for T-bet, a transcription
factor expressed primarily by CD4þ , and also by CD8þ
T and dendritic cells (Lugo-Villarino et al., 2003; Sullivan
et al., 2003), was also increased in TGFb1-expressing tumors,
as was IFNg, even though we did not detect a change in IFNg
expression in CD4þ and gdþ T cells. There was also
increased expression of NKG2D, an activating surface
receptor for gd T cells, and the NKG2D ligands H60 and
Rae-1 (Hayday, 2009) in papillomas overexpressing TGFb1.
TGFb1 induces proinflammatory and Th17-polarizing cytokines
in premalignant keratinocytes
To test whether TGFb1 production by premalignant tumor
cells could drive a proinflammatory cytokine environment,
we infected DT or ST primary keratinocytes with a retrovirus
expressing v-rasHa, as this mimics premalignant keratinocytes
in vitro and in vivo (Roop et al., 1986; Dlugosz et al., 1994).
In conditioned media from DT keratinocytes treated with dox
for 3 days, there was between 600 and 1,800 pg ml1 active
TGFb1, but this was undetectable in other groups. Figure 3a
shows that induction of TGFb1 in v-rasHa DT primary
keratinocytes elevated the expression of transcripts for the
Th17-polarizing cytokines IL-23p19 and IL-6, and for
the proinflammatory cytokines IL-1b and TNF-a, although
we did not determine whether activated IL-1b was secreted
by the keratinocytes. The increase in IL-23p19 was depen-
dent on autocrine TGFb1 signaling, as treatment of the
v-rasHa DT primary keratinocytes with SB431542, a small-
molecule inhibitor of the TGFb type-I receptor kinase,
reduced IL-23p19 mRNA by 15- to 20-fold (Figure 3b). There
was no significant difference in the expression of the other
subunit of IL-23, IL-12p40 (data not shown).
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Figure 1. Induction of TGFb1 in papillomas causes tumor regression.
Squamous papillomas were induced in 7- to 9-week-old K5/rTA tetOTGFb1
(DT) and K5/rTA (ST) mice. Tumor-bearing mice were placed on a dox diet
(1 g kg1) and analyzed after 48 hours or followed up for 10 days. (a) RT–PCR
analysis of tetOTGFb1 transgene expression in papillomas with or without
dox for 48 hours. (b) Immunohistochemical detection of phosphorylated
Smad2 using a p-Smad2-specific antibody. Bars¼ 20mM. (c) Quantitation of
nuclear Smad2 in papillomas expressing TGFb1 (*P¼0.02). (d) Tumor cell
proliferation in TGFb1-expressing papillomas after 48 hours (*Po0.01).
(e) Apoptosis in papillomas overexpressing TGFb1. Each histogram represents
the average percent of TUNEL-positive cells of four tumors (*P¼ 0.028).
(f) Changes in tumor volume over 10 days after TGFb1 induction. At least five
tumors were measured for each genotype (*P¼ 0.001), using one-way
repeated-measures analysis of variance. Error bars¼±SEM.
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When naive CD4þ T cells were activated in the presence
of media derived from a 3-day culture of v-rasHa DT primary
keratinocytes treated with dox, expression of IL-17A mRNA
increased by at least 2-fold and that of IL-17F by 4-fold
(Figure 3c), and there was a 3-fold increase in IL-17 secretion
as measured by ELISA (Figure 3d). Activation of T cells in the
presence of DTþdox-conditioned media and the TGFb1
type-I receptor (ALK5) inhibitor SB431542 blocked the
increase in secreted IL-17 (Figure 3d). Thus, TGFb1 signaling
in CD4þ T cells is required for Th17 polarization by
conditioned media from v-rasHa keratinocytes.
Induction of TGFb1 in papillomas causes a proinflammatory
microenvironment that is dependent on IL-17
We used microarray analysis of ST and DT papillomas to
determine whether a proinflammatory tumor microenviron-
ment was generated after induction of TGFb1. A total of
113 genes were identified as induced or suppressed by
1.3-fold or more in papillomas overexpressing TGFb1. As
expected, expression of several TGFb1 pathways and TGFb1
target genes was elevated in tumors expressing TGFb1
(Supplementary Table S1 online). However, despite the clear
reduction in tumor cell proliferation and increase in
apoptosis, there were minimal changes in genes associated
with cell cycle and apoptosis above the expression ratio
cutoff, but this could be due to the specific time point chosen
for analysis. By contrast, 36% of the induced genes (27 of 74)
were associated with inflammation, including genes asso-
ciated with leukocyte recruitment and chemotaxis, proteases
involved in inflammation, and markers of immune cells
(Supplementary Table S1 online). Although IL-17 was not
present on the array gene set, these results are consistent with
the increased IL-17 production determined by flow cytometry
and RT–PCR. We validated rapid induction of Chi3l-3, Ifi203,
and CCL8/MCP2 by quantitative PCR from tumor RNA and
used in situ hybridization to show increased expression of
CCL8 expression in the stroma of papillomas expressing
TGFb1 (Supplementary Figure S1 online). In parallel with this
proinflammatory gene signature, there was rapid increase in
inflammatory infiltrate in papillomas after induction of
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Figure 2. TGFb1 induces IL-17 production in CD4þ and cdþ tumor-infiltrating T cells. Tumor-infiltrating lymphocytes were isolated from papillomas
after 2 days of dox treatment and analyzed for cell-surface markers and intracellular cytokines. (a) A representative flow cytometry profile of IL-17þ and
IFNgþ T cells from ST and DT papillomas. (b) Percentage of IL-17þ and IFNgþ CD4þ T cells from ST (n¼11) and DT (n¼ 12) papillomas, and IL-17þ
gdþ T cells from ST (n¼ 4) and DT (n¼ 7) papillomas. (c) Expression of cytokine genes in ST and DT papillomas. For each gene, PCR reactions were
performed at the same time for all tumors, and products were run on the same agarose gel. GAPDH was used as loading control. Each column represents
the same tumor. Densitometry was performed on gel images for each gene using Kodak Molecular Imaging Software version 4.0, and intensity values
for each gene were normalized to the corresponding GAPDH value. Error bars¼±SEM.
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TGFb1, as judged from hematoxylin and eosin-stained
sections (Figure 4a and b), and this was in part due to an
increase in the number of myeloperoxidase (MPO)þ myeloid
cells (Figure 4c and d) and total CD3þ cells linked to
increased CD8þ but not CD4þ T cells (Figure 4g–i). Many of
the tumor-infiltrating CD3þ and CD8þ T cells were
associated with areas of tumor cell cytolysis (Figure 4e and
f). Flow cytometry analysis showed that, in addition to
changes in T-cell populations, elevated TGFb1 caused
increase in tumor-infiltrating macrophages (CD11bþ
CD11cF4/80þ ) (Figure 5a and b). Figure 5c and d show
that CD11bþ and CD11cþ cells, as well as CD44þCD62L
CD8þ effector cells and CD8þ IFNgþ cells, were also
increased in the inguinal lymph nodes (LNs) of tumor-bearing
mice after induction of TGFb1, suggesting that the major
response to TGFb1 was immune activation.
To test whether the inflammatory infiltrate induced by
TGFb1 was dependent on IL-17, we injected tumor-bearing
animals with a neutralizing anti-IL-17 antibody or isotype
control IgG and measured infiltrating myeloid cells 5 days
after induction of TGFb1. Figure 6a shows a representative
flow profile of infiltrating myeloid cells from control and
treated tumors that are quantitated in Figure 6b from multiple
tumors. Neutrophils (CD11bþ Ly6Gþ ) comprise the largest
percentage of infiltrating myeloid cells in control papillomas
without dox. After induction of TGFb1, the percentage of
infiltrating CD11bþ Ly6G nonneutrophil myeloid cells
increased significantly and there was parallel reduction in
the percentage of neutrophils. When mice were injected with
the neutralizing anti-IL-17 antibody, the TGFb1-dependent
increase in CD11bþ Ly6G myeloid cells with a similar side
scatter as CD11c F4/80þ cells was blocked, but the
percentage of neutrophils within the tumor did not change,
indicating both IL-17-dependent and IL-17-independent
effects of TGFb1 on different myeloid populations. However,
despite these changes, there was still a 25% reduction in the
average papilloma size in mice injected with the neutralizing
IL-17 antibody, suggesting that TGFb1 cytostatic effects were
paramount for regression at this stage of tumor development.
DISCUSSION
TGFb1 has well-documented effects on the adaptive and
innate immune response that are crucial not only in
promoting and resolving inflammation (Letterio and Roberts,
1998) but also for suppression of antitumor immunosurveil-
lance (Torre-Amione et al., 1990; Gorelik and Flavell, 2001).
Many studies have focused on immunosuppression by tumor-
derived TGFb1 as a mechanism for escape from immuno-
surveillance, but the effect of TGFb1 in a premalignant
context on antitumor immune responses is not well char-
acterized. Long-term overexpression of TGFb1 in the normal
epidermis causes an inflammatory response that resembles
atopic dermatitis (Fitch et al., 2009), but this is associated
with elevated proliferation compared with that in the normal
mouse epidermis. In this study, we have examined the effects
of acute TGFb1 overexpression in a benign premalignant
epidermal tumor that remains sensitive to TGFb1. Our results
show that increased expression of TGFb1 provokes rapid
growth arrest, tumor cell apoptosis, and regression, which
is coupled to increased expression of IL-17, increased CD8þ
T-cell and macrophage infiltration, and immune activation in
skin-draining LNs.
The rapid TGFb1-dependent increase in IL-17 production
by CD4þ T cells suggests that this represents in situ
differentiation of Th17 cells within the tumor microenviron-
ment rather than infiltration of Th17 cells. In support of this,
we observed an increase in the expression of transcripts for
IL-6 and IL-23, cytokines that polarize CD4þ T cells toward a
Th17 phenotype, in the presence of TGFb1 (Bettelli et al.,
2006; Mangan et al., 2006; Veldhoen et al., 2006).
Furthermore, increased expression of IL-6 and IL-23
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Figure 3. Autocrine TGFb1 induces proinflammatory and Th17-polarizing
cytokines in v-rasHa-expressing keratinocytes. ST and DT keratinocytes were
infected with the v-rasHa retrovirus and treated with dox to induce
TGFb1 expression and RNA or conditioned media isolated after 3 days.
(a) Quantitative RT–PCR analysis of cytokine gene expression in v-rasHa-
transduced primary keratinocytes. Induction of the tetOTGFb1 transgene is
shown by RT–PCR. (b) IL-23p19 expression in v-rasHa ST and DT keratinocytes
treated with dox and in the presence or absence of 1mM SB431542. Data in
panels a and b are derived from three independent experiments. Error
bars¼±SEM. (c) Expression of IL-17A and IL-17F mRNA by T cells activated
for 5 days in conditioned media from v-rasHa DT keratinocytes. (d) ELISA for
IL-17A/F in supernatants from T cells activated in conditioned media from
v-rasHa DT keratinocytes for 5 days, with and without 1 mM SB431542. Results
in panels c and d are representative of two independent experiments. IL-17
was not detected in the keratinocyte-conditioned media alone. All
quantitative PCR and data were normalized to GAPDH mRNA. For panel b,
data were log-transformed before statistical analysis.
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transcripts in premalignant v-rasHa keratinocytes and the
ability of conditioned media from these cells to induce IL-17
expression in naı¨ve CD4þ T cells suggest that cytokine
production by papilloma cells in response to autocrine
TGFb1 cooperates with TGFb1 to promote a Th17-polarizing
microenvironment. TGFb1 also increased the expression of
the proinflammatory cytokines TNF-a and IL-1b, and the
chemokine CCL8 (data not shown), in these cells, suggesting
that premalignant tumor cell response to TGFb1 also
contributes to the proinflammatory environment. As IL-17
stimulates proinflammatory cytokine expression by human
keratinocytes (Nograles et al., 2008), it is also possible that
Th17 differentiation within the tumor generates a positive
feedback loop further amplifying the Th17 response. In
support of this, non-lesional skin of mice injected with the
neutralizing anti-IL-17 antibody had a significantly decreased
number of Th17 cells (data not shown). Following induction
of TGFb1, the percentage of IL-17-producing gdþ T cells
within the tumor also increased 2.5-fold. gdþ T cells are
crucial for antitumor immunity in the skin and other mucosal
surfaces (Girardi, 2006), and are a major source of IL-17 in a
number of inflammatory conditions in the skin and other
tissues (Roark et al., 2008; Ito et al., 2009; O’Brien et al.,
2009). Although a direct link has not been established, this is
the first report of an association between TGFb1 and IL-17
production by gdþ T cells. As IL-1b and IL-23 cause IL-17
production by gdþT cells in the absence of T-cell receptor
(TCR) stimulation (Sutton et al., 2009), it is possible that their
upregulation in TGFb1-expressing tumors is important in gdþ
T-cell IL-17 production. Although speculative, it is also
possible that increase in H60 and Rae1 levels in TGFb1-
expressing tumors causes gdþ T-cell activation through the
NKG2D receptor, and a subsequent IL-17 increase.
The role of IL-17 and Th17 cells in cancer is controversial.
During tumor development, Th17 cells increase within the
tumor microenvironment (Kryczek et al., 2007), and both
IL-17 and IL-23 can induce proinflammatory and proangiogenic
cytokines (Jovanovic et al., 1998; Kolls and Linden, 2004;
Langowski et al., 2006) that could promote tumor growth and
progression. In the two-stage skin cancer model, neutralizing
antibodies to IL-17 suppress TPA-mediated hyperplasia and
delay papilloma formation, suggesting that IL-17 is important
for TPA-induced tumor promotion (Xiao et al., 2009).
However, overexpression of IL-17 can suppress tumor
development in experimentally induced tumor models, and
adoptive transfer of Th17 cells can mediate tumor regression
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Figure 4. TGFb1 overexpression increases inflammatory infiltrate in benign tumors. ST papillomas (a, c) and DT papillomas (b, d–f) were harvested from
mice placed on dox for 1 week. Tumors were stained with hematoxylin and eosin-Y (a, b), antiMPO for myeloid cells (c, d), and anti-CD3e (e) and anti-CD8
(f). Bars¼ 20mM. The arrows indicate infiltrating leukocytes. The photomicrographs are representative of at least three different tumors per genotype.
S, stroma; T, tumor. (g–i) Quantitation of tumor-infiltrating T cells from immunohistochemical analysis for CD3þ (g), CD4þ (h), and CD8þ (i) cells.
No staining was detected in the absence of primary antibody. Each histogram represents the average from at least four tumors of each genotype, with
more than five fields counted per section. Error bars¼±SEM.
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(Benchetrit et al., 2002; Muranski et al., 2008; Kryczek et al.,
2009a, b; Martin-Orozco et al., 2009). Our results show that
expression of TGFb1 by premalignant tumor cells causes an
IL-17-dependent increase in tumor-infiltrating CD11bþ
Ly6G myeloid cells that are predominantly macrophages
(CD11bþF4/80þCD11c phenotype and scatter profile).
This is supported by microarray results, as macrophages are
the major source of chitinase-3L-3 in the skin (HogenEsch
et al., 2006). Recently, Th17 cells were shown to improve
tumor immunosurveillance by promoting infiltration of
antigen-presenting cells into tumors and antigen presentation
in tumor-draining LNs, leading to a strong CD8þ T-cell
response (Martin-Orozco et al., 2009). The increase in
CD11bþ , CD11cþ , CD8þ effectors, and IFNgþ CD8þ cells
in skin-draining LNs suggests that infiltration of macrophages
in TGFb1-expressing tumors induces a similar antitumor
immune response in these mice. In support of the CD8þ
T-cell response in LN, we detected higher CD8þ cell
numbers by immunohistochemistry in TGFb1-expressing
tumors (Figure 4i). Although flow cytometry analysis showed
that 50–70% of tumor-infiltrating CD8þ T cells were positive
for IFNg (data not shown), the low overall CD8þ numbers
within the tumors prevented detection of significant changes
in cytokine production after induction of TGFb1.
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CD11bþ Ly6Gþ populations in tumors from each treatment group (n¼3 for DTþ IC; n¼ 6 for DTþ doxþ IC; and n¼7 for DTþdoxþ anti-IL-17). Error
bars¼±SEM. IC, IgG isotype control.
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Several studies have implicated both immature monocytic
and mature neutrophils as having a suppressor phenotype
that promotes cancer development (Movahedi et al., 2008;
Youn et al., 2008), and a recent study of xenografted
malignant mouse cancers showed that TGFb1 signaling
within the tumor can drive neutrophils toward a protumori-
genic phenotype similar to the M2 macrophage (Fridlender
et al., 2009). However, our results show that in a benign
tumor, TGFb1 expression decreased the tumor-infiltrating
CD11bþ Ly6Gþ neutrophils independent of IL-17. Although
further studies will be required to determine whether these
infiltrating neutrophils have a pro- or antitumorigenic
phenotype, taken together, these results suggest that, at early
stages of cancer the effect of TGFb1 signaling on myeloid
populations is distinct from that in malignant cancers, and is
predominantly polarized toward an antitumor immune
response. As tumor regression still occurred when TGFb1-
induced macrophage infiltration was blocked by IL-17
neutralization, it is possible that TGFb1 reduction of the
IL-17-independent neutrophil population coupled with cyto-
static effects of TGFb1 on benign tumor cells can still drive
regression. Further studies using keratinocytes with defective
TGFb1 signaling, as well as specific depletion of each of
these myeloid populations, will be important to determine
the relative contribution of TGFb1-mediated immune re-
sponse or cell-autonomous cytostatic response to tumor
regression. Nevertheless, our results suggest that TGFb1
expression within the premalignant tumor microenvironment
drives an antitumor immune phenotype through IL-17-
dependent and IL-17-independent effects on distinct myeloid
cell populations.
MATERIALS AND METHODS
Analysis of tumors
Tumors were induced according to standard protocols (Hennings
et al., 1993) (see the Supplementary Methods online for details).
Tumor cell proliferation was detected using anti-BrdU immunohis-
tochemistry as described by Liu et al. (2001), and quantitated as the
percentage of BrdU-positive cells in the basal layer of the tumor. At
least five fields from each tumor with 75–100 cells were counted for
each tumor. Apoptotic cells were detected using a dig-UTP-based
TUNEL assay as described by Negoescu et al. (1996), with protease
pretreatment. No TUNEL-positive cells were detected in the absence
of TdT enzyme or antidigoxygenin antibody. TUNEL-positive cells
were expressed as the percent of total tumor cells per section. For
immunohistochemistry, anti-human MPO (Dako, Carpinteria, CA);
anti-CD3e (Santa Cruz Biotechnology, Santa Cruz, CA); CD4 and
CD8 (Angio-Proteomie, Boston, MA); and anti-phospho Smad2
(Santa Cruz Biotechnology) antibodies were used on 70% ethanol-
fixed sections after antigen retrieval. No staining was detected in the
absence of primary antibody. Positive cells were quantitated in
multiple fields per section with at least five different tumors per
group. At least 200–300 total cells were counted per section and four
sections per tumor were averaged.
Cell culture
ST and DT primary keratinocytes were cultured as previously
described (Shukla et al., 2008) and after 3 days were infected with
the c2ras retrovirus as described by Bae et al. (2009). To induce
TGFb1 expression, keratinocytes were cultured with 1mg ml1 dox
for 3 days and total RNA was isolated, or culture supernatant was
collected and concentrated using the Amicon Ultra-4 centrifugal
device (Millipore Corp., Billerica, MA). The concentrate was
reconstituted with RPMI medium (Mediatech Inc., Manassas, VA)
and used for activation of T cells.
Flow cytometry analysis of LN cells and tumor-infiltrating
leukocytes
Leukocytes from individual papillomas were extracted after enzy-
matic digestion of tumors using collagenase-I and IV (Worthington,
Lakewood, NJ), hyaluronidase, and DNase-I in complete RPMI
medium and incubated at 371C for 45 minutes. Tumor cells were
stained with antibodies against mouse CD45, CD11b, F4/80
(eBioscience, San Diego, CA), CD11c, and Ly6G (BD Pharmingen,
San Diego, CA) in two different combinations, whereas inguinal LN
cells were stained for CD11b and CD11c. For cytokine staining, LNs
and tumor cells were stimulated with 50 ng ml1 phorbol 12-
myristate 13-acetate and 1 mg ml1 ionomycin (Sigma, St Louis, MO)
in the presence of GolgiStop (BD Pharmingen) for 4.5 hours and
stained with anti-mouse CD45, CD4, or gd TCR (eBioscience) and
fixed overnight in 4% paraformaldehyde. After staining for IFNg and
IL-17 (BD Pharmingen) in 0.2% saponin buffer, cells were analyzed
using a Cytomics FC500 (Beckman Coulter, Fullerton, CA). Dead
tumor cells were excluded from analysis using the Live/Dead fixable
red dead cell stain kit (Invitrogen, Carlsbad, CA). To neutralize IL-17,
tumor-bearing mice were injected with 100 mg of IgG isotype control
antibody (clone 54447) or mouse anti-IL-17 (clone 50104; R&D
Systems, Minneapolis, MN) intraperitoneally with 1 g kg1 dox chow
for 5 days.
Isolation and activation of naive T cells
CD4þCD62Lþ T cells were purified from the spleen of FVB/n mice
using magnetic-activated cell sorting (Miltenyi Biotech, Bergisch
Gladbach, Germany) and activated using CD3/CD28 Dynabeads
(Invitrogen, Carlsbad, CA). T cells were activated in media derived
from a 3-day culture of v-rasHa DT primary keratinocytes with or
without dox in a 96-well plate (105 cells well1) for 5 days. The ALK5
inhibitor, SB431542, was added to the T cells, when indicated, at
1mM on days 0, 2, and 4. Cells from multiple wells within the same
group were pooled and harvested for RNA isolation and T-cell
supernatants were collected and stored at 801C.
ELISA
Cytokine levels in the conditioned media or T-cell supernatants
were measured using the Human/Mouse TGFb1 ELISA kit and the
Mouse IL-17A ELISA kit (eBioscience) following the manufacturer’s
protocol.
Gene expression analysis
RNA from tumors and cells was isolated and semi-quantitative
RT–PCR was performed as described by Darwiche et al. (2007).
Quantitative RT–PCR was performed using the PerfeCta SYBR Green
Supermix for iQ (Quanta Biosciences, Gaithersburg, MD) using a
MyIQ Real-Time PCR Detection System (Bio-Rad Laboratories,
Hercules, CA). All samples were run in duplicate, with values
normalized to that of glyceraldehyde-3-phosphate dehydrogenase
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(GAPDH). For primer sequences and microarray methods, see
the Supplementary Methods online. The data set for this study has
been deposited at NCBIs Gene Expression Omnibus:GEO
http://www.ncbi.nlm.nih.gov/geo/ and is accessible through GEO
Series accession number GSE4195.
Statistical analysis
Unpaired t-test was used to compare two groups, and one-way
analysis of variance with Tukey’s post-test was used to compare
more than two groups.
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